Orexo AB   Report issue

For profit Phase 2 Phase 3 Phase 4
Founded: Stockholm Sweden (1995)
Status: No NME R&D (1995)

Organization Overview

First Clinical Trial
2008
NCT00758446
First Marketed Drug
2013
naloxone (narcan)
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Orexa BV | Orexo AB | OREXO US INC

Active Ingredients

Marketed Drugs (2)

buprenorphine (2013)

naloxone (narcan) (2013)

Drugs in Phase 4 Trials (2)

buprenorphine (3 trials)

fentanyl (Innovar) (1 trial)

Drugs in Phase 3 Trials (1)

naloxone (narcan) (2 trials)

Drugs in Phase 2 Trials (3)

Key: Orexo AB (2) Acquired (1)

blx-028914 (1 trial)

cetirizine (zyrtec) (1 trial)

lidocaine (xylocaine) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Opioid-Related Disorders (Phase 4)

Rhinitis (Phase 2)

Rhinitis, Allergic (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 7
  • # of Trial APIs: 6